Lilly to Boost Mounjaro Access in India Amid Rising Obesity

• Eli Lilly plans to expand access to its obesity and diabetes drug Mounjaro (tirzepatide) across India due to accelerating demand for GLP-1 medicines.
• Lilly India President Winslow Tucker emphasized scaling availability, building awareness, and ensuring responsible use of Mounjaro, launched in India in March last year.
• Nearly 100 million people in India are living with obesity or overweight, a major health concern linked to cardiovascular disease and other complications.
• Tucker stressed that Mounjaro is a prescription drug requiring medical supervision and does not support cosmetic or unsupervised use.
• Lilly is focused on scaling its reach across India, including a partnership with Cipla to expand access beyond major urban centers, as India could become a large GLP-1 market.